Arcus Biosciences, Inc. (RCUS)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: United States
Exchange: NYSE
Market cap: $3.21B
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Latest financial period: June 30, 2026
Filed with the SEC: August 5, 2026
Estimated earnings date: October 27, 2026
Not currently ranked. Cannot calculate: sales growth
Profit Not currently ranked
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROIC | -94.5% | -77.6% | -68.4% | -83.8% |
Growth Not currently ranked
Payout Not currently ranked
Safety Not currently ranked
Price Not currently ranked
